# US 7,465,784 B2 · Antimicrobial peptides and methods of identifying the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,465,784 B2
- Document ID: US7465784B2
- Status: Granted
- Kind: B2
- Application number: 11/586,943
- Filed: 2006-10-26
- Published: 2008-05-29
- Granted: 2008-12-16
- Earliest claimed: 2006-10-26
- Assignees: Board of Regents of the University of Nebraska
- Inventors: Guangshun Wang
- Web page: https://patentgrep.com/patent/US7465784B2

## CPC

- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antimicrobial peptides and methods of identifying the same are provided.

## Claims

### Claim 1

An isolated LL-37 peptide having the amino acid sequence FKRIVQRIKDFLRX1 (SEQ ID NO: 10), wherein X1 is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, and 8 amino acids, and wherein at least one of the amino acids at position 4, 8, and 12 is a D-amino acid.

### Claim 2 (depends on 1)

The isolated LL-37 peptide of claim 1, wherein X1 is selected from the group consisting of 0, 1, 2, 3, 4, and 5 amino acids.

### Claim 3 (depends on 1)

The isolated LL-37 peptide of claim 1, wherein X1 is the amino acid sequence NLV (SEQ ID NO: 11).

### Claim 4 (depends on 1)

The isolated LL-37 peptide of claim 1, wherein said peptide is SEQ ID NO: 7, wherein the isoleucine at position 4, the isoleucine at position 8, and the leucine at position 12 are D-amino acids.

### Claim 5 (depends on 1)

The isolated LL-37 peptide of claim 1, wherein the amino acids of X1 are the corresponding amino acids of SEQ ID NO: 1.

### Claim 6 (depends on 1)

The isolated LL-37 peptide of claim 1, wherein the isoleucine at position 4, the isoleucine at position 8, and the leucine at position 12 are D-amino acids.

### Claim 7 (depends on 1)

The isolated LL-37 peptide of claim 1, wherein said LL-37 peptide comprises D-amino acids spaced by three consecutive L-amino acids.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising at least one LL-37 peptide of claim 1 and at least one pharmaceutically acceptable carrier.